Acellular pertussis vaccine safety and efficacy in children, adolescents and adults

Drugs

Volumn 65, Issue 10, 2005, Pages 1367-1389

  Casey, Janet R ^a,b   Pichichero, Michael E ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; ANTHRAX VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; LYME DISEASE VACCINE; MEASLES MUMPS RUBELLA VACCINE; PENTAVAC; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; RABIES VACCINE; TETANUS TOXOID; TRIAVAC; TRIPACEL; TYPHOID VACCINE; YELLOW FEVER VACCINE;

AGE DISTRIBUTION; ANTIBODY RESPONSE; ANTIBODY TITER; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECONOMIC ASPECT; EPIDEMIOLOGICAL DATA; ERYTHEMA; FOLLOW UP; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE REACTION; LIMB SWELLING; LONG TERM CARE; META ANALYSIS; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PERTUSSIS; PRURITUS; REVIEW; RISK ASSESSMENT; RISK FACTOR; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIALS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; TREATMENT OUTCOME; WHOOPING COUGH;

HAEMOPHILUS INFLUENZAE SEROTYPE B;

EID: 22944442951     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565100-00005     Document Type: Review

References (165)

1. Lennart G, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996 Feb; 334 (6): 349-55
2. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996 Feb; 334 (6): 341-8
3. Olin P, Rasmussen F, Gustafsson L, et al. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 1997 Nov; 350 (9091): 1569-77
4. Trollfors B, Taranger J, Largergard T, et al. A placebo-controlled trial of pertussis-toxoid vaccine. N Engl J Med 1995 Oct 19; 333 (16): 1045-50
5. Simondon F, Presiosi M, Yam A, et al. A randomized double-blind trial comparing a two component acellular to whole cell pertussis vaccine in Senegal. Vaccine 1997; 15 (15): 1606-12
6. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics Jan 1998; 101 (1 Pt 1): 1-11
7. Schmidt HJ, von Konig CHW, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996 Jan 3; 275 (1): 37-41
8. Liese J, Meschievitz C, Harzer E, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 1997; 16 (11): 1038-44
9. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J 1997; 16 (4 Suppl.): 90-6
10. Cherry JD, Heininger U, Stehr K, et al. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics 1998; 102 (4 Pt 1): 909-12
11. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 21 (17-18): 2003-14
12. Cherry J, Gornbein J, Heininger U, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16 (20): 1901-6
13. Storsaeter J, Hallander HO, Gustafsson L, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16 (20): 1907-16
14. Deen JL, Mink CM, Cherry J, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis 1995; 21: 1211-9
15. Hellwig MM, Rodriguez ME, Berbers GAM, et al. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis 2003 Sep 1; 188: 738-42
16. Hellwig SMM, van Spriel AB, Schellekens JFP, et al. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect Immun 2001 Aug; 69 (8): 4846-50
17. Plotkin S, Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatr Infect Dis J 1997; 16 (5): 508-17
18. Taranger J, Trollfors B, Lagergard T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000; 181: 1010-3
19. Mills KHG, Barnard A, Watkins J, et al. Cell-mediated Immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993 Feb; 61 (2): 399-410
20. De Magistris MT, Romano M, Nuti S, et al. Dissecting human T-cell responses against Bordetella species. J Exp Med 1988; 168: 1351-62
21. Tommaso AD, Bartalini M, Peppoloni S, et al. Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults. Vaccine 1997; 15 (11): 1218-24
22. Mills KHG, Ryan M, Ryan E, et al. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998 Feb; 66 (2): 594-602
23. Peterson JW, Ibsen PH, Bentzon MW, et al. The cell-mediated and humoral immune response to vaccination with acellular and whole-cell pertussis vaccine in adult humans. FEMS Microbiol Immunol 1991; 3 (5): 279-87
24. Podda AL, Nencioni MT, DeMagistris A, et al. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J Exp Med 1990 Sep; 172: 861-8
25. DeMagistris MT, Romano M, Nuti S, et al. Dissecting human T-cell responses against Bordetella species. J Exp Med 1998; 168 (1351): 372-80
26. Peterson JW, Holm A, Ibsen PH, et al. Identification of human T-cell epitopes on the S4 subunit of pertussis toxin. Infect Immun 1992; 160: 3962-70
27. Peppoloni S, Nencioni L, Di Tommaso A, et al. Lymphokine secretion and cytotoxic activity of human DC4 T-cell clones against Bordetella pertussis. Infect Immun 1991; 160: 3962-70
28. Ausiello CM, Lande R, la Sala A, et al. Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens. J Infect Dis 1998; 178: 466-70
29. Ryan M, Murphy G, Gothefors L, et al. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis 1997; 175: 1246-50
30. Zepp F, Knuf M, Habermehl P, et al. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 1996 Oct; 64 (10): 4078-84
31. Cassone A, Ausiello CM, Urbani F, et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Arch Pediatr Adolesc Med 1997 Mar; 151: 283-9
32. Ausiello C, Urbani F, LaSala A, et al. Vaccine-and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 1997 Jun; 65 (6): 2168-74
33. Ausiello CM, Lande R, Urbani F, et al. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J Infect Dis 2000; 181: 189-95
34. Medical Research Council. Vaccination against whooping cough. BMJ 1959; 1: 994-1000
35. Medical Research Council. Vaccination against whooping cough: relation between protection in children and results of laboratory tests. BMJ 1956; 2: 454-62
36. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month old children. Pediatrics 1997 Nov; 100 (5): 772-88
37. Meade BD, Lynn F, Reed GF, et al. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines. Pediatrics 1995 Sep; 96 (3): 595-600
38. Pichichero M, Hall C, Insel R. A mucosal antibody response following systemic Haemophilus influenzae type B infection in children: the American Society for Clinical Investigation, Inc. J Clin Invest 1981 May; 67 (5): 1482-9
39. Olin P, Gustafsson L, Barreto L, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003; 21: 2015-21
40. Salmaso S, Mastrantonio P, Wassilak SGF, et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Vaccine 1998; 13 (13): 1270-5
41. Salmaso S, Mastrantonio P, Tozzi AE, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Stage III Working Group. Pediatrics Nov 2001; 108 (5): e81
42. Taranger J, Trollfors B, Lagergard T, et al. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J 1997; 16: 180-4
43. Lugauer S, Heininger U, Cherry JD, et al. Long-term clinical effectiveness of acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002; 161: 142-6
44. Liese JG, Stonjanov S, Peters A, et al. Duration of efficacy after primary immunization with Biken Acellular Pertussis Vaccine [abstract no. G-2050]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago, 302
45. Giuliano M, Mastrantonio P, Giammanco A, et al. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 1998 Jun; 132 (6): 983-8
46. Okada K, Ueda K, Morokuma K, et al. Comparison of antibody titers in eleven-to-twelve-year-old Japanese school children six years after administration of acellular and whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Pediatr Infect Dis J 1998 Dec; 17 (12): 1167-8
47. Meyer CU, Guiso N, Begue P, et al. Cell-mediated Immunity in children 2.5 to 5 years of age 1-3 years after vaccination with either DTaP or DTwP based combination vaccines in France [abstract no. 43]. Proceedings of the 40th Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 17-20; Toronto, 240
48. Esposito S, Agliardi T, Giammanco A, et al. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun 2001 Jul; 69 (7): 4516-20
49. Carlsson R, Claesson BA, Fagerlund E, et al. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 2002; 21: 535-41
50. Taranger J, Trollfors B, Begfors E, et al. Mass vaccination of children with pertussis toxoid: decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001 Oct 1; 33: 1004-10
51. Ntazayabo B, Deserres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003; 22: 22-7
52. Isomura S. Efficacy and safety of acellular pertussis vaccine in Aichi prefecture, Japan. Pediatr Infect Dis J 1998; 7: 258-62
53. Blennow M, Granstrom M. Adverse reactions and serologic response to a booster dose of acellular vaccine in children immunized with acellular or whole-cell vaccine as infants. Pediatrics 1989; 84: 62-7
54. Bernstein HH, Rothstein EP, Pichichero ME, et al. Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4, and 6 month old infants in the United States. Vaccine 1995; 13: 1631-5
55. Halperin SA, Mills E, Barreto L, et al. Acellular pertussis vaccine as a booster dose for seventeen to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four, and six months of age. Pediatr Infect Dis J 1995; 14: 792-7
56. Halpern SA, Eastwood JB, Barreto L, et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine 1996; 14: 767-72
57. Schmitt HJ, Muschenborn S, Wagner S, et al. Immunogenicity and reactogenicity of a bicomponent and a tricomponent acellular pertussis-diphtheria-tetanus (DTaP) vaccine in primary immunization and as second year booster: a double-blind randomized trial. Int J Infect Dis 1996; 1: 6-13
58. Schmitt HJ, Beutel K, Schuind A, et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr 1997; 130: 616-23
59. Pichichero ME, Edwards KM, Anderson EL, et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in 4- to 6-year-old children. Pediatrics 2000; 105 (1): e11
60. Rennels MC, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000, 105; e12
61. Liese JG, Stojanov S, Berutb F, et al. Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP-T-HBs) administered at 2, 4, 6 and 12-14 months of age: Munich Vaccine Study Group. Vaccine 2001; 20: 448-54
62. Jackson LA, Carste BA, Malais D, et al. Retrospective population-bases assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr Infect Dis J 2002; 21: 781-5
63. Rennels MB, Deloria MA, Pichichero ME, et al. Lack of consistent relationship between quantity of aluminum in diphtheria-tetanus-acellular pertussis vaccines and rates of extensive swelling reactions. Vaccine 2002; 20: S44-7
64. Ciofi Degli Atti MA, Salmaso S, Cotter B, et al. Reactogenicity and immunogenicity of adult versus pediatric diphtheria and tetanus booster dose at 6 years of age. Vaccine 2001; 20: 74-9
65. Nelson K, Goldman JA, Perlino CA. Severe local reactions to pneumococcal vaccine. South Med J 1980; 73: 264-5
66. Brachman PS, Gold H, Plotkin SA, et al. Field evaluation of a human anthrax vaccine. Am J Public Health 1962; 52: 632-45
67. Woo EJ, Burwen DR, Gatumu SNM, et al. Extensive limb swelling after immunization: reports to the vaccine adverse event reporting system. Clin Infect Dis 2003; 37: 351-8
68. Scheifele DW, Guasparini R, Lavigne P. A comparative study of PENTA™ vaccine booster doses given at 12, 15, or 18 months of age. Vaccine 1999; 17: 543-50
69. Noble GT, Bernier RH, Esber EC. Acellular and whole-cell pertussis vaccines in Japan. JAMA 1987; 257: 1351-6
70. Hedenskog S, Bjorksten B, Blennow M, et al. Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole-cell and an acellular pertussis vaccine. Int Arch Allergy Appl Immunol 1989; 89: 156-61
71. Gupta RK, Siber GR. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 1995; 13: 1263-76
72. Odelram H, Gransrom M, Hedenskog S, et al. Immunoglobulin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminum content of the vaccines. Pediatr Allergy Immunol 1994; 5: 118-23
73. Edelman K, Malmstrom K, He Q, et al. Local reactions and IgE antibodies to pertussis toxin after acellular DTP immunization. Eur J Pediatr 1999 Dec; 158 (12): 989-94
74. Schiefele DW, Halperin SA, Ferguson AC. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine 1995; 13: 4720-6
75. Halperin SA, Scheifele D, Barreto L, et al. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J 1999; 18: 772-9
76. Van der Wielen M, Damme PV, Joossens E, et al. A randomized controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 2000; 18: 2075-82
77. Schmitt HJ, Mohnike K, Zepp F, et al. Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults. Vaccine 2001; 19 (4-5): 403-8
78. Halperin SA, Smith B, Russell M, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000 Feb 4; 18 (14): 1312-9
79. Rothstein EP, Anderson EL, Decker MD, et al. An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Vaccine 1999; 17: 2999-3006
80. Edwards KM, Decker MD, Graham BS, et al. Adult Immunization with acellular pertussis vaccine. JAMA 1993; 269: 53-6
81. American Academy of Pediatrics. Recommended Childhood and Adolescent Immunization Schedule-United States, 2003. Pediatrics 2003; 111 (1): 212-4
82. Amir J, Melamed R, Bader J, et al. Immunogenicity and safety of a liquid combination of DT-PRP-T vs. lyophilized PRP-T reconstituted with DTP. Vaccine 1997; 15 (16): 149-54
83. Avendano A, Ferreccio C, Lagos R, et al. Haemophilus Influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis at two, four, and six months of age. Pediatr Infect Dis J 1993; 12: 638-43
84. Centers for Disease Control and Prevention. FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children. MMWR Morb Mortal Wkly Rep 1993; 42: 296-8
85. Centers for Disease Control and Prevention. FDA approval of use of Haemophilus influenzae type b conjugate vaccine reconstituted with diphtheria-tetanus-pertussis vaccine for infants and children. MMWR Morb Mortal Wkly Rep 1993; 42 (49): 964-5
86. Clemens JD, Ferreccio C, Levine MM, et al. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA 1992; 267 (5): 673-8
87. Dagan R, Botujansky C, Watemberg N, et al. Safety and immunogenicity in young infants of Haemophilus b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Pediatr Infect Dis J 1994; 13: 356-62
88. Eskola J, Kayhty H, Gordon LK, et al. Simultaneous administration of Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine with routine diphtheria-tetanus-pertussis and inactivated poliovirus vaccinations of childhood. Pediatr Infect Dis J 1998; 7: 480-4
89. Ferreccio C, Clemens J, Avendano A, et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine co-administered in the same syringe with diphtheriatetanus toxoid pertussis vaccine at 2, 4, and 6 months of age. Pediatr Infect Dis J 1991; 10 (10): 764-71
90. Gold R, Scheifele D, Barreto L, et al. Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoid pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four, and six months of age. Pediatr Infect Dis J 1994; 13 (5): 348-55
91. Hoppenbrouwers K, Lagos R, Swennen B, et al. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine 1998; 16: 921-7
92. Jones IG, Tyrrel H, Hill A, et al. Randomized controlled trial of combined diphtheria, tetanus, whole-cell pertussis vaccine administered in the same syringe and separately with Haemophilus influenzae type b vaccine at two, four, and six months of age. Vaccine 1998; 16: 109-13
93. Levine OS, Lagos R, Losonsky GA, et al. No adverse impact on protection against pertussis from combined administration of Haemophilus influenzae type b conjugate and diphtheria-tetanus toxoid-pertussis vaccine sin the same syringe. J Infect Dis 1996; 174: 1341-4
94. Mulholland EK, Anhonkhai VI, Greenwood AM, et al. Safety and immunogenicity of Haemophilus influenzae type-b Neisseria meningitis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in your Gambian infants. Pediatr Infect Dis J 1993; 12: 632-7
95. Mulholland EK, Hoestermann A, Ward JI, et al. The use of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine mixed with diphtheria-tetanus-pertussis vaccine in Gambian infants. Vaccine 1996; 14 (9): 905-9
96. Paradiso PR, Hogerman DA, Madore DV, et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics 1993; 92 (6): 827-32
97. Scheifele D, Barreto L, Meekison W, et al. Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? CMAJ 1993; 149: 1105-12
98. Schiefele D, Bjornson G, Barreto L, et al. Controlled trial of Haemophilus influenzae type b diphtheria toxoid conjugate combined with diphtheria, tetanus, and pertussis vaccine, in 18-month-old children, including comparison of arm versus thigh injection. Vaccine 1992; 10: 455-60
99. Watemberg N, Dagan R, Arbelli Y, et al. Safety and immunogenicity of Haemophilus influenzae type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr Infect Dis J 1991; 10: 758-63
100. Eskola J. Analysis of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis combination vaccines. J Infect Dis 1996; 174 Suppl. 3: 302-5
101. Kayhty H, Eskola J, Peltola H, et al. Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type be capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid. J Infect Dis 1997; 155: 100-6
102. Lepow ML, Peter G, Glode MP, et al. Response of infants to Haemophilus influenzae type b polysaccharide and diphtheria-tetanus-pertussis vaccines in combination. J Infect Dis 1984; 149: 950-5
103. Bell F, Martin A, Blondeau C, et al. Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunization. Arch Dis Child 1996; 75: 298-303
104. Kovel A, Wald ER, Guerra N, et al. Safety and immunogenicity of acellular diphtheria-tetanus-pertussis and Haemophilus conjugate vaccines given in combination or at separate injection sites. J Pediatr 1992; 120: 84-7
105. Halperin SA, Barreto L, Eastwood BJ, et al. Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate. Vaccine 1997; 15: 295-300
106. Greenburg DP, Wong VK, Partridge S, et al. Evaluation of a new combination vaccine that incorporates diphtheria-tetanus-acellular pertussis (DTaP), hepatitis B (HB) and Haemophilus influenzae type b (Hib) conjugate (PRP-T) vaccines [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco
107. Schmitt HJ, Bock H, Boegaets H, et al. Single injection of a combined DTPa-Hep B and Hib tetanus conjugate vaccine: a feasibility study [abstract no. G64]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco
108. Shinefiled H, Black S, Ray P, et al. Safety of combined acellular pertussis DTaP-HbOC vaccine (Lederle-Praxis) in infants [abstract no. G72]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco
109. Schmitt HJ, Zepp F, Muschenborn S, et al. Immunogenicity and reactogenicity of Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr 1998; 157 (3): 208-14
110. Eskola J, Olander RM, Hovi T, et al. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996; 348 (9043): 1688-92
111. Goldblatt D, Richmond P, Millard E, et al. The induction of immunology memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J Infect Dis 1999; 180 (2): 538-41
112. Bell F, Heath P, Shackley F, et al. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). Vaccine 1998; 16 (6): 637-42
113. Rennels MB, Hohenboken M, Reisinger KS, et al. Comparison of acellular pertussis-diphtheria-tetanus toxoids and Haemophilus influenzae type b vaccines administered separately vs. combined in younger vs. older toddlers. Pediatr Infect Dis J 1998; 17: 164-6
114. Mills E, Gold R, Thipphawong J, et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four, and six-months of age. Vaccine 1998; 16: 576-85
115. Pichichero ME, Passador S. Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine. Clin Infect Dis 1997; 25: 1378-84
116. Pichichero ME, Shelly MA, Treanor JJ. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr Infect Dis J 1997; 16: 72-4
117. Pichichero ME, Latiolais T, Bernstein DI, et al. Vaccine antigen interactions after a combination DTaP/PRP-T vaccine in 2, 4, and 6-month infants. Pediatr Infect Dis J 1997; 16 (9): 863-70
118. Pichichero ME, Voloshen T, Passador S. Kinetics of booster responses to Haemophilus type b vaccination in infants. Pediatr Infect Dis J 1999; 18: 1106-8
119. Halperin SA, Davies D, Barreto L. Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen to nineteen month old infants. J Pediatr 1997; 130: 525-31
120. Moxon ER, Murphy PA. Haemophilus influenzae bacteremia and meningitis resulting from survival of a single organism. Proc Natl Acad Sci U S A 1978; 75: 1534-6
121. Garner D, Weston V. Effectiveness of vaccination for Haemophilus influenzae type b. Lancet 2003; 361: 395-6
122. Aristegui J, Dal-Re R, Garrote E, et al. Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis b (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type be conjugate vaccine, to infants at 2, 4, and 6 months of age. Vaccine 1998; 16: 1976-81
123. Faldella G, Alessandroni R, Magini GM, et al. The preterm infant's antibody response to a combined diphtheria, tetanus, acellular pertussis, and hepatitis B vaccine. Vaccine 1998; 16: 1646-9
124. Giammanco G, Moiraghi A, Zotti C, et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine administered according to two different primary vaccination schedules. Vaccine 1998; 16: 722-6
125. Kanra G, Ceyhan M, Ecevit Z, et al. Primary vaccination of infants with a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine. Pediatr Infect Dis J 1995; 14 (11): 998-1000
126. Melnick JL. International prospects for combined vaccines with emphasis on quadrivalent diphtheria-tetanus-pertussis-hepatitis B vaccine. Ann N Y Acad Sci 1995; 754: 267-72
127. Usonis V, Bakasenas V, Willems P, et al. Feasibility study of a combined diphtheria-tetanus-acellular pertussis-hepatitis B (DTPa-HBV) vaccine, and comparison of clinical reactions and immune responses with diphtheria-tetanus- acellular pertussis-hepatitis B (DTPa-HBV) vaccine, and comparison of clinical reactions and immune responses with diphtheria-tetanus-acellular pertussis (DTPa) and hepatitis B vaccines apresponse plied as mixed or injected into separate limbs. Vaccine 1997; 15: 1680-6
128. Begue P, Stagnara J, Vie-Le-Sage F, et al. Immunogenicity and reactogenicity of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccines given concurrently with Haemophilus type b conjugate vaccine or as a pentavalent vaccine. Pediatr Infect Dis J 1997; 16: 787-94
129. Begue PC, Grimprel EM, Giovannangeli MD, et al. Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus- acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus- inactivated poliovirus vaccine in preadolescents. Pediatr Infect Dis J 1998; 17: 804-9
130. Schmitt HJ, Knuf M, Oritz E, et al. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000; 137: 304-12
131. Halperin SA, King J, Law B, et al. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis 1999; 28: 995-1001
132. Pertussis: United States 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51 (4): 73-6
133. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28: 1230-7
134. Yih WK, Lett SM, des Vignes FN, et al. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J Infect Dis 2000; 182: 1409-16
135. National, state and urban area vaccination coverage levels among children aged 19-35 months: United States, April 1994-March 1995. MMWR Morb Mortal Wkly Rep 1996; 45 (7): 145-50
136. Bass JW, Wittler RR. Return of epidemic pertussis in the United States. Pediatr Infect Dis J 1994; 13: 343-5
137. Marchant CD, Loughlin AM, Lett SM, et al. Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis 1994; 169: 1297-305
138. Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 1990; 161: 480-6
139. Mertsola J, Ruuskanen O, Eroloa E, et al. Interfamilial spread of pertussis. J Pediatr 1983; 103: 359-63
140. Addis DG, Davis JP, Meade BD, et al. A pertussis out break in a Wisconsin nursing home. J Infect Dis 1991; 164: 704-10
141. Mink CM, Serota NM, Nugent S. Outbreak of pertussis in a fully immunized adolescent and adult population. Arch Pediatr Adoles Med 1994; 148: 153-7
142. Etkind P, Lett SM, MacDonald PD, et al. Pertussis out breaks in groups claiming religious exemptions to vaccinations. Am J Dis Child 1992; 146: 1073-6
143. Strebel P, Nordin J, Edwards K, et al. Population based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001; 183: 1353-9
144. Bisgard KM, Ciantirini CL, Pascual FB, et al. Infant pertussis: who is the source? Prospective investigation of cases from GA, IL, MN, MS January 1999-October 2000 [abstract]. Pediatr Res 2001; 19: 100A
145. Lambert HJ. Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep 1965; 80: 365-9
146. Fario KM, Cochi SL, Zell ER, et al. Epidemiologic features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992; 14: 708-19
147. Cromer BA, Goydos J, Hackell J, et al. Unrecognized pertussis infection in adolescents. Am J Dis Child 1993; 147: 575-7
148. Deville JG, Cherry JD, Christenson PD, et al. Frequency of unrecognized Bordetella pertussis infection in adults. Clin Infect Dis 1995; 32: 1961-7
149. Senzilet D, Halperin SA, Skika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001; 32: 1691-7
150. Mink CAM, Cherry JD, Christenson P, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992; 14: 464-71
151. Jackson LA, Cherry JD, Wang SPECT, et al. Frequency of serological evidence of Bordetella infections and mixed infections with other respiratory pathogens in University students with cough illnesses. Clin Infect Dis 2000; 31: 3-6
152. Jansen DL, Gray GC, Putnam SD, et al. Evaluation of pertussis in US Marine Corps Trainees. Clin Infect Dis 1997; 25: 1099-107
153. Vincent JM, Cherry JD, Nauschuetz WF, et al. Prolonged a febrile nonproductive cough illnesses in American soldiers in Korea: a serological search for causation. Clin Infect Dis 2000; 30: 534-9
154. Swowronski DM, Serres GD, MacDonald D, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis 2002; 185: 1448-53
155. Halperin SA, Smith B, Russell M, et al. An adult formation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000; 18: 1312-9
156. Keitel WA, Muenz LR, Decker MD, et al. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis 1999; 180: 397-403
157. Minh NNT, He Q, Edelman K, et al. Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults. Vaccine 2000; 18: 1971-4
158. National Advisory Committee on Immunization. Statement on adult/adolescent formulation of combined acellular pertussis, tetanus, and diphtheria vaccine. Can Commun Dis Rep 2000; 26: 1-8
159. Campins-Marti M, Cheng HK, Forsyth K, et al. Recommendations are needed for adolescent and adult pertussis immunization: rationale and strategies for consideration. Vaccine 2001; 20: 641-6
160. Ward JI, Cherry JD, Chang S, et al. US NIH Adolescent and Adult Acellular Pertussis Efficacy Trial. N Engl J Med. In Press
161. Pichichero ME, Treanor J. Economic impact of pertussis. Arch Pediatr Adolesc Med 1997; 151: 35-40
162. Lee LH, Pichichero ME. Costs of illness due to Bordetella pertussis in families. Arch Fam Med 2000; 9: 989-96
163. Pertussis-related hospitalizations, complications, and deaths, by age group: United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51: 73-6
164. Pichichero ME, Casey JR, Hoeger WJ. Efficacy of azithromycin for evaluation of pertussis with assessment of disease morbidity and work productivity [abstract no. 6458]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago
165. Ekwueme DU, Strebel PM, Hadler SC, et al. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med 2000; 154: 797-803